1. Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.107
Figure 4 Strategies for utilizing dendritic cells to target autoreactive T cells
Figure 4 | Strategies for utilizing dendritic cells to target autoreactive T cells. Autologous tolerogenic dendritic cells (tolDCs) can be generated from autologous monocytes loaded with autoantigens or by tolerizing DCs using nanoparticles coupled to tolerogenic autoepitope peptides. These cells induce differentiation and expansion of regulatory T (Treg) cells. Alternatively, engineered plasmid DNA encoding the autoantigen can be injected intramuscularly into patients; after uptake by tolDCs, the autoepitopes are presented to autoreactive T cells, resulting in T cell suppression and/or differentiation into Treg cells
Pozsgay, J. et al. (2017) Antigen-specific immunotherapies in rheumatic diseases
Nat. Rev. Rheumatol. doi: /nrrheum